+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Myasthenia Gravis (MG) - Epidemiology Forecast to 2027

  • ID: 4618388
  • Report
  • Region: Global
  • 177 Pages
  • DelveInsight
1 of 2
‘Myasthenia Gravis (MG) - Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Myasthenia Gravis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered:
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2016-2027

Myasthenia Gravis Epidemiology

The Myasthenia Gravis (MG) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Myasthenia Gravis are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Myasthenia Gravis Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology {total prevalent cases, gender-specific cases, severity-specific prevalent cases [Class I, Class II (Class IIa, IIb), Class III (Class IIIa, IIIb), Class IV & Class V], auto-antibodies specific prevalent cases [Anti-AchR Ab (+ve), Anti-MuSK Ab (+ve), Double seronegative] and diagnosed cases} scenario of Myasthenia Gravis (MG) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According this research, total prevalent population of Myasthenia Gravis (MG) in 7 major markets was found to be 129, 267 in 2016.

Report Scope
  • The report covers detailed overview of Myasthenia Gravis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Myasthenia Gravis in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by Severity i.e., Class I (Ocular), Class II (Mild generalized), Class III (Moderate generalized), Class IV (Severe generalized) and Class V (Intubated) Myasthenia Gravis in 7MM
Key strengths
  • 10 Year Forecast of Myasthenia Gravis epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of MG
  • Prevalent Cases according to segmentation: Severity-specific prevalence and autoantibodies-specific prevalence
  • Diagnosed cases of MG
Key assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Myasthenia Gravis Market Overview at a Glance

3. Market Share (%) Distribution of MG in 2017

4. Market Share (%) Distribution of MG in 2027

5. Disease Overview: Myasthenia Gravis
5.1. Introduction
5.2. Types of Myasthenia Gravis
5.3. MGFA Classification of Myasthenia Gravis
5.4. Etiology
5.5. Genetic Basis of Myasthenia Gravis
5.6. Risk Factors
5.7. Signs and Symptoms
5.8. Pathophysiology of Myasthenia Gravis
5.9. Comorbid conditions in MG
5.10. Diagnosis

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Population and Forecast Parameters
6.3. 7MM Total Prevalent Patient Population of Myasthenia Gravis
6.4. Country Wise-Epidemiology of Myasthenia Gravis
6.4.1. United States
6.4.2. Assumptions and Rationale
6.4.3. Prevalent cases of Myasthenia Gravis in the United States
6.4.4. Gender-specific Prevalent Cases of Myasthenia Gravis in the US
6.4.5. Diagnosed cases of Myasthenia Gravis in the US
6.4.6. Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis in the US
6.4.7. Autoantibodies- specific Diagnosed Prevalent cases of Myasthenia Gravis in the US
6.4.8. Germany
6.4.9. Assumptions and Rationale
6.4.10. Prevalent cases of Myasthenia Gravis in Germany
6.4.11. Gender-specific Prevalent Cases of Myasthenia Gravis in Germany
6.4.12. Diagnosed cases of Myasthenia Gravis in Germany
6.4.13. Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis in Germany
6.4.14. Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in Germany
6.4.15. France
6.4.16. Assumptions and Rationale
6.4.17. Prevalent cases of Myasthenia Gravis in France
6.4.18. Gender-specific Prevalent Cases of Myasthenia Gravis in France
6.4.19. Diagnosed cases of Myasthenia Gravis in France
6.4.20. Severity-specific Prevalent Cases of Myasthenia Gravis in France
6.4.21. Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in France
6.4.22. Italy
6.4.23. Assumptions and Rationale
6.4.24. Prevalent cases of Myasthenia Gravis in Italy
6.4.25. Gender-specific Prevalent Cases of Myasthenia Gravis in Italy
6.4.26. Diagnosed cases of Myasthenia Gravis in Italy
6.4.27. Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis in Italy
6.4.28. Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in Italy
6.4.29. Spain
6.4.30. Assumptions and Rationale
6.4.31. Prevalent cases of Myasthenia Gravis in Spain
6.4.32. Gender-specific Prevalent Cases of Myasthenia Gravis in Spain
6.4.33. Diagnosed cases of Myasthenia Gravis in Spain
6.4.34. Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis in Spain
6.4.35. Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in Spain
6.4.36. United Kingdom
6.4.37. Assumptions and Rationale
6.4.38. Prevalent cases of Myasthenia Gravis in the United Kingdom
6.4.39. Gender-specific Prevalent Cases of Myasthenia Gravis in the United Kingdom
6.4.40. Diagnosed cases of Myasthenia Gravis in the United Kingdom
6.4.41. Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis in the UKAS
6.4.42. Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in the UK
6.4.43. Japan
6.4.44. Assumptions and Rationale
6.4.45. Prevalent cases of Myasthenia Gravis in Japan
6.4.46. Gender-specific Prevalent Cases of Myasthenia Gravis in Japan
6.4.47. Diagnosed cases of Myasthenia Gravis in Japan
6.4.48. Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis in Japan
6.4.49. Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in Japan

7. Market Drivers

8. Market Barriers

9. Appendix

10. Report Methodology

11. The Publisher Capabilities

12. Disclaimer

13. About the publisher
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll